Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London
Wednesday, November 12, 2025 1 min read
Key Takeaway: Kiniksa Pharmaceuticals will present at the Jefferies Global Healthcare Conference in London on November 17, 2025. The presentation will be accessible via a live webcast on the company's website, with a replay available shortly after. Kiniksa is dedicated to developing therapies for unmet medical needs, particularly in cardiovascular indications.
Price reaction · baseline $40.58 (2025-11-12 close) · hit after-hours · clean, no other KNSA news in the window
day 0 close · peak
-0.7%
Conference Participation Details
Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat
How to Access
Investors and the general public can listen to both sessions live at:
Archived versions will be available following the live events for a limited time.
Market Sentiment Analysis
POSITIVE FACTORS
Kiniksa Pharmaceuticals is actively engaging with investors.
The presentation at a major conference highlights their commitment to transparency.
The company focuses on unmet medical needs in cardiovascular diseases.
Full Press Release Details
LONDON, Nov. 12, 2025 (GLOBE NEWSWIRE) --Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will present at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 2:30 p.m. Greenwich Mean Time (9:30 a.m. Eastern Time).
A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website atwww.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
About KiniksaKiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visitwww.kiniksa.com.